Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes
Interventions: Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair; Industry
Eligibility: 24 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Neoplasms, Breast Neoplasms, Breast Cancer
Interventions: AZD8931, anastrozole, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Diabetes Mellitus
Interventions: SDH Tool; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PTM-101; Drug
Lead sponsor: PanTher Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more

Conditions: Diabetes Mellitus, Type 1
Interventions: HDV-Insulin Lispro and Insulin Degludec (-40%), HDV-Insulin Lispro and Insulin Degludec (-10%); Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: San Mateo, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions: Inhaled Technosphere Insulin; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: Nutrition, Type 2 Diabetes, T2DM, T2DM (Type 2 Diabetes Mellitus), Diabetes Education, Diabetes Type 2, Diabetes Mellitis
Interventions: CGM-Augmented FIM, FIM only; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depression, Diabetes Mellitus
Interventions: Technology-supported care; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: El Monte, California • Lancaster, California • Long Beach, California + 4 more

Conditions: Vulvar Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
Interventions: Intervention group triads; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Pancreatic Neoplasm
Interventions: Acquire EUS Biopsy Device, SharkCore Biopsy System; Device
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Adrenal Insufficiency
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hyperprolactinemia, Spontaneous Intracranial Hypotension
Interventions: Pituitary panel will be drawn pre-op and post-op for all patients.; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression
Interventions: Nurse-led case management, Treatment as usual; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Quality, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: Educational video and pamphlet, Traditional genetic counseling; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Adrenomyeloneuropathy, Adrenoleukodystrophy
Interventions: Lorenzo's oil; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus
Interventions: DSMES Intervention; Behavioral
Lead sponsor: Villanova University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Villanova, Pennsylvania

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: NNC 90-1170; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions: Apraclonidine 1.0% ophthalmic solution; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
Interventions: LXH254, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Cardiovascular Diseases, Diabetes
Interventions: SGLT2 inhibitor, GLP-1 RA, Education-First; Drug · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 27 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NAFLD
Interventions: NAFLD-specific weight loss intervention, Wait-list control; Behavioral · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine

Diabetes-Depression Care-management Adoption Trial

Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery

Comparison of Two Fine Needle Biopsy Needles for Solid Pancreatic Masses

Physiological Response of Cortisol to Cardiac Catheterization

Pituitary Function and Spontaneous Intracranial Hypotension

Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression

Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling

Taste Bud-Derived Stem Cells in Humans

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy

Screening and Nutrition for Patients With Diabetes: A Pilot Study

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

Iopidine to Decrease Intraocular Pressure Rise After Injections

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men